The interaction of 40 with HIF-1α, a key regulator of tumor adaptation to hypoxic conditions, suggests that it inhibits cancer cell survival by targeting the HIF-1α pathway, making it a promising candidate for selective anticancer therapy. This evidence concerns the gene HIF1A and cancer.